Treats asthma as prophylactic therapy. ANDA 213811, held by Amneal Ireland Ltd. Beclomethasone Dipropionate.
As of Nov 16, 2026, ANDA 213811 (Beclomethasone Dipropionate), held by Amneal Ireland Ltd, was first approved by FDA on Dec 16, 2025, with 0 approved supplements and 0 published complete response letters.
Beclomethasone dipropionate HFA inhalation aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations of Use: Beclomethasone dipropionate HFA inhalation aerosol is NOT indicated for the relief of acute bronchospasm. Beclomethasone dipropionate HFA inhalation aerosol is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations: Not indicated for the relief of acute bronchospasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 16, 2025 | Original application | Approved |
| Beclomethasone Dipropionate0.04MG/INH · aerosol, metered;inhalation | Beclomethasone Dipropionate | Rx |
| Beclomethasone Dipropionate0.08MG/INH · aerosol, metered;inhalation | Beclomethasone Dipropionate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters